Responses
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
640 Combinatorial chemoimmunotherapy based on the antibody-cytokine fusion protein L19TNF unleashes potent anti-tumor immunity against treatment-refractory glioblastoma
Compose a Response to This Article
Other responses
No responses have been published for this article.